Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 61 of 6351
-
Could caffeine help save newborn brains? major trial launches
Disease control Recruiting nowCHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an u…
Phase 3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New stroke drug could boost recovery when given hours after symptoms
Disease control Recruiting nowThis randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well…
Phase 3 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Gene therapy may free gaucher patients from lifelong infusions
Disease control Recruiting nowThis study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the effica…
Phase 3 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Gene therapy breakthrough offers hope for Transfusion-Free life in thalassemia
Disease control Not yet recruitingThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major
Phase 2 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Oxygen chambers could save lives from Flesh-Eating bacteria
Disease control Recruiting nowNecrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades. The standard of care in NSTI is multidisciplinary and includes surge…
Phase 4 • Sponsor: Ole Hyldegaard • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved a…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Gene therapy aims to restore hearing in deaf children
Disease control Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase 1/2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for tough breast cancer: immune booster after chemo may keep cancer away
Disease control Not yet recruitingThe phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC) patients with residual disease (non-pCR) after neoa…
Phase 3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New 6-Month TB drug cocktail could replace Year-Long ordeal
Disease control Not yet recruitingThe FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional regimen in a French historical cohort of MDR-TB pa…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New dual heart pump offers hope for patients with End-Stage heart failure
Disease control Not yet recruitingAdvanced heart failure is a life-threatening condition characterized by the inability of one or both ventricles to maintain adequate blood circulation. In such cases, medical treatments often prove ineffective, necessitating advanced treatment. Heart transplantation is the standa…
Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Donor cells take on tough leukemia in new trial
Disease control Not yet recruitingThis phase 1/2 study is testing a new treatment for acute myeloid leukemia (AML) that has come back or has not responded to other treatments. The treatment uses specially modified immune cells (called CD33 CAR-NK cells) from a healthy, unrelated donor to attack the cancer. The f…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
AI reads ECGs to catch deadly aortic tear in minutes
Diagnosis Not yet recruitingThe goal of this prospective multicenter observational study is to learn whether an artificial intelligence model based on electrocardiograms (ECGs) can help diagnose acute type A aortic dissection (TAAD) in adults who come to the emergency department with chest pain or related s…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:09 UTC
-
New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
Disease control Recruiting nowExtranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patie…
Phase 1/2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising immunotherapy trial aims to replace harsh chemo for kids with relapsed leukemia
Disease control Not yet recruitingThe IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements. The …
Phase 3 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
Disease control Recruiting nowProtocol Title: A Prospective, Randomized Controlled Study of Venetoclax Plus 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Plus "2+6" DA Versus "3+7" DA Regimen in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Objective: This is a prospective, open-label, ran…
Phase 3 • Sponsor: The Second Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a malaria drug boost immunotherapy for a tough skin cancer?
Disease control Recruiting nowThis study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma. The primary objectives are to assess the objective response …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can engineered immune cells lock in remission for aggressive lymphoma?
Disease control Recruiting nowThe purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
Phase 2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can an immune booster outsmart High-Risk bone cancer?
Disease control Recruiting nowProspective, open, interventional, randomized, non-commercial trial
Phase 2 • Sponsor: Anna Raciborska • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Electric pulses may fight bile duct cancer without heat
Disease control Recruiting nowIrreversible electroporation is a non-thermal ablative technology that uses high-voltage electric pulses to create permanent nanopores in tumor cell membranes, leading to apoptosis or other forms of cell death. Because the mechanism is primarily non-thermal, IRE may better preser…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a tiny dose of a blood thinner cut stroke risk in seniors?
Prevention Not yet recruitingThe overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to help prevent recurrent strokes. However, an antipl…
Phase 3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC